NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Zami Aberman, Chairman, President and CEO, has been invited by the Equity Forum in Stuttgart, Germany to present updates on the Company's corporate development in Germany and its Phase I clinical trials using the Company’s placental-derived stem cell product, PLX-PAD. Mr. Aberman will also discuss the arrangements with Charité – Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for the upcoming Critical Limb Ischemia (CLI) clinical trials in Germany. The presentation, which is organized by the Deutsche Börse and the KfW SME Bank, will be held on April 29, 2009.
